We are evaluating the long-term safety and effectiveness of amlitelimab for individuals with moderate to severe atopic dermatitis who have participated in earlier studies. This research aims to better understand how the treatment works over time.
We are studying whether propranolol can help reduce anxiety in patients undergoing surgery for pancreatic cancer and if it affects tumor-related changes. This trial will compare the effects of propranolol to a placebo in a small group of participants.
We are testing a new treatment called CLN-049 for patients with acute myeloid leukemia who have measurable residual disease. This study aims to find the right dose and assess its safety.
We are testing a new drug called Bleximenib for people with acute leukemia to find the best dose and check its safety. We also want to see if it helps improve treatment outcomes.
We are testing a new drug, bleximenib, combined with current therapies for patients with acute myeloid leukemia who have certain genetic changes. The goal is to find the best dose and ensure it is safe for use.
We are studying whether a single daily dose of immunosuppressive medication is as effective as a twice-daily dose for liver transplant recipients. This trial also compares two different formulations of tacrolimus to see which works better.
We are investigating a new treatment for patients with advanced solid tumors. The goal is to see if it can improve outcomes compared to current therapies.
We are examining how sleep disorders and body temperature changes may indicate the progression of Alzheimer's disease in people with Down syndrome. This research could help identify early signs of the disease.
We are studying whether adding ticagrelor to aspirin helps reduce heart-related events in patients after coronary artery bypass surgery. This trial also looks at the risk of bleeding and graft failure.
We are studying whether a lower initial dose of a cancer medication is effective for older breast cancer patients compared to the standard dose. This trial aims to improve treatment outcomes and quality of life for vulnerable patients.
We are comparing single and combination therapies for patients with ulcerative colitis who didn't respond to previous treatment. The goal is to see which option may help achieve better remission and quality of life.
We are studying different ways to reduce rituximab doses in patients with rheumatoid arthritis. The goal is to find the best method to lower disease impact and activity.
We are studying whether a low dose of a specific medication can help prevent complications in elderly patients with blood cancers receiving stem cell transplants. This trial aims to improve recovery and overall outcomes after the transplant.
We are testing a new drug, BMS-986458, for people with relapsed or refractory non-Hodgkin lymphoma. The study aims to understand its safety and how it works alone and with other treatments.
We are testing a new combination of medications for patients with HER2-positive gastric or gastroesophageal cancer. The goal is to see if it helps clear cancer markers and improves survival compared to standard chemotherapy.
We are investigating whether a combination of evening melatonin and morning light therapy can help adults with idiopathic hypersomnia feel less sleepy. This study compares the treatment to a placebo to see if it makes a difference.
We are studying whether colchicine and thiamine can help improve heart health in people with heart failure due to ischemic heart disease. The trial looks at their effects on serious heart-related events and hospital visits.
We are studying a new combination treatment for HLA-A2 negative metastatic uveal melanoma to see if it works better than current options. The trial will also evaluate the safety and quality of life for participants.
We are evaluating the safety of a new treatment combining tiragolumab and atezolizumab for patients with certain stages of non-small cell lung cancer after surgery and chemotherapy. This study compares it to a placebo treatment to see how well it works.
We are studying whether stopping a treatment for prostate cancer after 12 months is as effective as continuing it. This may help reduce side effects and costs for patients with low-volume metastatic castration-sensitive prostate cancer.